Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MSc, Helen Won, MS, Julie Teruya-Feldstein, MD, Michael Berger, PhD, Talal T Khawaja, BS, Mario E Lacouture, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 2876.

https://doi.org/10.1182/blood.V122.21.2876.2876

Published: 2013

Journal Articles

EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains

Wendy Béguelin, PhD, Matt R. Teater, MS, Katerina Hatzi, PhD, Relja Popovich, PhD, Yanwen Jiang, PhD, Karen L. Bunting, PhD, Monica Rosen, Hao Shen, MD, Shao Ning Yang, Young Rock Chung, MSc, Rita Shaknovich, MD/PhD, Caretha Creasy, Randy D. Gascoyne, MD, Leandro Cerchietti, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Jonathan D. Licht, MD, Olivier Elemento, PhD, Ari M. Melnick, MD

Blood (2013) 122 (21): 1.

https://doi.org/10.1182/blood.V122.21.1.1

Published: 2013

Journal Articles

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

Stephen S. Chung, MD, Jae H. Park, MD, Eunhee Kim, PhD, Young Rock Chung, MSc, Wenhuo Hu, PhD, Piro Lito, MD, PhD, Julie Teruya Feldstein, MD, Raajit K. Rampal, M.D., Ph.D., Leon Telis, Minal Patel, Neal Rosen, Christopher Y. Park, M.D., Ph.D., Martin S. Tallman, MD, Omar Abdel-Wahab, MD

Blood (2013) 122 (21): 816.

https://doi.org/10.1182/blood.V122.21.816.816

Published: 2013

Journal Articles

Identification Of Markers Of Thrombotic Risk and Response To Cytoreductive Intervention In Philadelphia-Chromosome Negative Myeloproliferative Neoplams

Gabriela Soriano Hobbs, MD, Minal Patel, Young Rock Chung, MSc, Omar Abdel-Wahab, MD, Gerald A. Soff, MD, Raajit K. Rampal, M.D., Ph.D.

Blood (2013) 122 (21): 3627.

https://doi.org/10.1182/blood.V122.21.3627.3627

Published: 2013

Journal Articles

Conditional Deletion of Asxl1 Results in Myelodysplasia

Omar Abdel-Wahab, M.D., Jie Gao, PhD, Mazhar Adli, PhD, Young Rock Chung, MSc, Richard Koche, PhD, Alan H. Shih, MD, PhD, Suveg Pandey, BSc, Lindsay M. La-Fave, PhD, Delphine Ndiaye-Lobry, Yu Sup Shin, BSc, Parva K. Bhatt, BSc, Jay P. Patel, Xinyang Zhao, PhD, Christopher Y. Park, MD, PhD, Jacob D. Jaffe, PhD, Bradley E. Bernstein, MD, PhD, Iannis Aifantis, PhD, Ross L. Levine

Blood (2012) 120 (21): 308.

https://doi.org/10.1182/blood.V120.21.308.308

Published: 2012

NARROW

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

Identification Of Markers Of Thrombotic Risk and Response To Cytoreductive Intervention In Philadelphia-Chromosome Negative Myeloproliferative Neoplams

Conditional Deletion of Asxl1 Results in Myelodysplasia

Email alerts

ASH Publications

American Society of Hematology

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

Identification Of Markers Of Thrombotic Risk and Response To Cytoreductive Intervention In Philadelphia-Chromosome Negative Myeloproliferative Neoplams

Conditional Deletion of Asxl1 Results in Myelodysplasia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only